Healthcare stocks finished moderately higher with the NYSE
Healthcare Sector Index adding 0.5% and shares of healthcare
companies in the S&P 500 climbing 0.6% as a group.
In company news, Australia-based oncology biotechnology firm
Prima BioMed (
) jumped in U.S. trading Thursday, climbing 44% to finish at $1.68
a share after a protocol update in a study of its epithelial
ovarian cancer treatment candidate CAN-004.
The company says multiple jurisdictions have now approved its
amended CAN-004 protocol including regulators in Latvia, Lithuania,
Bulgaria, Ukraine and Belarus. The CAN-004 trial was approved by
the Belgian regulators in January.
The CAN-004 amendment has also been approved by a number of
ethics committees and institutional review boards, including sites
in the United States, Australia, Belgium, Bulgaria, Latvia, and
Lithuania. Prior to enrolling patients into the amended CAN-004
protocol, a positive review is required from the competent
regulatory authority and the ethics committee for each site, the
In other sector news,
(-) TEVA, Gives in to profit-taking despite a 5% increase in the
drug-maker's quarterly dividend and Q4 results above Street
expectations and Q4 results that beat analyst forecasts.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.